Found 35 clinical trials
Dolutegravir-Lamivudine for na ve HIV-Infected Patients With 200 CD4/mm3
Protocol Title: DOLCE: Dolutegravir-Lamivudine for nave HIV-Infected Patients with 200 CD4/mm3 Protocol Number: FH-57 Study Objectives: To assess the antiviral activity at week 48
- 0 views
- 04 Oct, 2021
- 4 locations
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
/emtricitabine to dolutegravir/lamivudine
- 0 views
- 26 Jan, 2021
- 1 location
Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides
in patients with SOR to second-line antivirals Lamivudine (LAM)/ Telbivudine (LdT)/ Adefovir Dipivoxil (ADV) and its combinations with other second-line antivirals for 24 weeks, or SOR to the first
- 0 views
- 21 Feb, 2022
- 10 locations
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence
, high HBV viral load is associated with the risk of HCC recurrence after surgical resection, especially on late recurrence. In one previous randomized controlled trial, patients who received lamivudine
- 0 views
- 19 Jul, 2021
- 4 locations
Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B
types of antiviral drugs: α-interferons (plain and pegylated ([PEG-IFN]α-2a or α-2b) interferons) and nucleos(t)ide analogues (NUC) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV
- 0 views
- 07 Apr, 2022
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (DYNAMIC)
The purpose of this study is to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV
- 0 views
- 14 May, 2022
- 55 locations
BFTAF Elderly Switch Study (BFTAF)
BACKGROUND: Current Kenya National Anti-retroviral (ARV) Guidelines and World Health Organization (WHO) Guidelines recommend first-line therapy of tenofovir disoproxil fumarate (TDF), lamivudine
- 0 views
- 22 Mar, 2022
- 2 locations
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
part of the fixed dose combination (FDC) of DOR/lamivudine (3TC)/tenofovir disproxil fumarate (TDF) in participants ≥6 to <12 years and weighing ≥14 to <45 kg. The second primary objective is to
- 0 views
- 13 Apr, 2022
- 13 locations
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase
- 188 views
- 23 Mar, 2022
- 15 locations
Body Composition Sub-study of the D2EFT Trial
This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will offer …
- 9 views
- 21 Feb, 2022
- 7 locations